Clinical Trial

AMT-116 in Patients with Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 17, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and efficacy of AMT-116 monotherapy in subjects with advanced solid tumors. The study is divided into two parts: the part I is dose escalation and the Part Ⅱ for expansion.
Trial Details
NCT Number NCT06782334
Lead Sponsor Multitude Therapeutics Inc.
Conditions Advanced Solid Tumors
Enrollment 144 participants
Start Date 2024-05-07
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2025-01-17